Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients

Abstract To predict outcome to combination bevacizumab (BVZ) therapy, we employed cell-free DNA (cfDNA) to determine chromosomal instability (CIN), nucleosome footprints (NF) and methylation profiles in metastatic colorectal cancer (mCRC) patients. Low-coverage whole-genome sequencing (LC-WGS) was p...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Tom Venken, Ian S. Miller, Ingrid Arijs, Valentina Thomas, Ana Barat, Johannes Betge, Tianzuo Zhan, Timo Gaiser, Matthias P. Ebert, Alice C. O’Farrell, Jochen Prehn, Rut Klinger, Darran P. O’Connor, Brian Moulton, Verena Murphy, Garazi Serna, Paolo G. Nuciforo, Ray McDermott, Brian Bird, Gregory Leonard, Liam Grogan, Anne Horgan, Nadine Schulte, Markus Moehler, Diether Lambrechts, Annette T. Byrne
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2024-05-01
Serija:	npj Genomic Medicine
Online dostop:	https://doi.org/10.1038/s41525-024-00415-x
Oznake:	Označite Brez oznak, prvi označite!